ProCE Banner Activity

Current PARP Inhibitor Indications for Advanced Ovarian Cancer

Clinical Thought

Read this commentary for my thoughts on recent developments and current indications for PARP inhibitors as maintenance treatment in the frontline setting or after recurrence of advanced ovarian cancer.

Released: February 02, 2024

Share

Faculty

Colleen Bohnenkamp

Colleen Bohnenkamp, PharmD, BCOP, BCPS

Oncology Clinical Pharmacist
The University of Kansas Health System
Kansas City, Kansas

Provided by

Provided by ProCE, LLC, in partnership with Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, GSK, ImmunoGen, Inc., Merck Sharp & Dohme LLC, and Novocure, Inc.

AstraZeneca

GSK

ImmunoGen, Inc.

Merck Sharp & Dohme, LLC

Novocure, Inc

Partners

Clinical Care Options, LLC

ProCE Banner

Faculty Disclosure

Primary Author

Colleen Bohnenkamp, PharmD, BCOP, BCPS

Oncology Clinical Pharmacist
The University of Kansas Health System
Kansas City, Kansas

Colleen Bohnenkamp, PharmD, BCOP, BCPS, has no relevant financial relationships to disclose.